Compare Expensify Inc (EXFY) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs 22nd Century Group Inc — how do they compare? Expensify Inc trades at $2.4 (market cap $208.82M), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Expensify Inc is far larger — about 335.9× 22nd Century Group Inc's market cap, and Expensify Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and 22nd Century Group Inc for 32 Days on average.
| EXFY | XXII | |
|---|---|---|
Market Cap | $208.82M | $621.67K |
Volume | 456,102 | 45,625 |
Sector | Technology | Consumer Staples |
52-Week High | $2.72 | $483.00 |
52-Week Low | $0.75 | $0.80 |
Typical Hold Time | 41 Days | 32 Days |
Enterprise Value | $148.44M | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.40, up 5.73% today, showing technical bullish momentum with positive moving averages. The company reported mixed quarterly results with recent beats but maintains negative profitability metrics. Recent business developments include strategic AI integrations and European expansion of its corporate card program, signaling growth initiatives despite ongoing net losses.
The outlook remains speculative with analyst consensus pointing to significant upside potential ($13.75 target) but fundamental challenges persist including negative margins and cash flow volatility. Key risks include execution on AI transition and competitive pressure in expense management software, while institutional sentiment leans bullish with 50% buy ratings.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
